COMMUNIQUÉS West-GlobeNewswire

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

24/12/2024 - 01:22

• 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025; • Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application (“ [...]

XBiotech suspend son programme de rhumatologie

24/12/2024 - 01:53

Des résultats de l’étude sur la polyarthrite rhumatoïde récemment conduite soulèvent des questions AUSTIN, Texas, 24 déc. 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ : XBIT) a annoncé aujourd’hui qu’elle suspendait son [...]

Guardion Health Sciences Announces Declaration of Cash Distribution

23/12/2024 - 21:55

HOUSTON, TEXAS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) today announced that its Board of Directors declared a cash distribution (the “Distribution”) in an amount [...]

ALPHA PRO TECH, LTD. ANNOUNCES $2 MILLION EXPANSION OF SHARE REPURCHASE PROGRAM

23/12/2024 - 22:00

NOGALES, Ariz., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Alpha Pro Tech, Ltd. (NYSE American: APT) , a leading manufacturer of products designed to protect people, products and environments, including disposable protective [...]

Anika To Participate in 43rd Annual J.P. Morgan Healthcare Conference

23/12/2024 - 22:01

BEDFORD, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and [...]

AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds

23/12/2024 - 22:02

VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin [...]

Abivax Announces a Change to the Composition of its Board of Directors

23/12/2024 - 22:05

Abivax Announces a Change to the Composition of its Board of Directors PARIS, France, December 23, 2024, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage [...]

Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million

23/12/2024 - 22:05

WEST LAFAYETTE, Ind., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”) , a leading contract research organization specializing in nonclinical and analytical drug discovery and development [...]

Ceribell to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

23/12/2024 - 22:05

SUNNYVALE, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]

Solid Biosciences Added to the Nasdaq Biotechnology Index

23/12/2024 - 22:05

CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]

CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

23/12/2024 - 22:30

MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43 rd Annual J.P. Morgan [...]

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

23/12/2024 - 22:30

TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 43 rd Annual J.P. Morgan [...]

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

23/12/2024 - 22:49

BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“ Neuphoria ” or the “ Company ”) is pleased to announce that its previously announced scheme of arrangement in relation [...]

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD

23/12/2024 - 17:30

Study to assess ability of GAL-101 eye drops in slowing or stopping the growth of geographic atrophy, a severe form of age-related macular degeneration Trial planned to enroll 110 patients in the US, Europe, and Israel [...]

Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis

23/12/2024 - 18:58

HALIFAX, Nova Scotia and SPRING, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Scientists at Dalhousie University in Halifax, and Io Therapeutics, Inc. in Spring Texas, announced today collaborative publication of data from [...]

NewGen Progresses Reverse Merger Plans with Engagement of Legal Teams and Updated Timeline

23/12/2024 - 13:30

BANGKOK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”) today announced that both parties involved in the previously announced reverse merger with European Wellness [...]

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

23/12/2024 - 13:30

Promising results support VYN202’s potential as a novel, once-daily oral treatment for a broad range of immune-mediated disorders Consistent with Phase 1a SAD results, VYN202 demonstrated a favorable safety and [...]

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease

23/12/2024 - 13:30

The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia Phase 1b clinical trial will assess safety and tolerability along with biomarkers during three months of dosing with GT- [...]

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

23/12/2024 - 13:30

Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheet NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today [...]